Literature DB >> 15755899

NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.

Ying-Wei Lin1, Christopher Slape, Zhenhua Zhang, Peter D Aplan.   

Abstract

The myelodysplastic syndromes (MDSs) are a group of clonal hematopoietic stem-cell disorders characterized by ineffective hematopoiesis and dysplasia. A wide spectrum of genetic aberrations has been associated with MDS, including chromosomal translocations involving the NUP98 gene. Using a NUP98-HOXD13 fusion gene, we have developed a mouse model that faithfully recapitulates all of the key features of MDS, including peripheral blood cytopenias, bone marrow dysplasia, and apoptosis, and transformation to acute leukemia. The MDS that develops in NUP98-HOXD13 transgenic mice is uniformly fatal. Within 14 months, all of the mice died of either leukemic transformation or severe anemia and leucopenia as a result of progressive MDS. The NUP98-HOXD13 fusion gene inhibits megakaryocytic differentiation and increases apoptosis in the bone marrow, suggesting a mechanism leading to ineffective hematopoiesis in the presence of a hypercellular bone marrow. These mice provide an accurate preclinical model that can be used for the evaluation of MDS therapy and biology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755899      PMCID: PMC1201424          DOI: 10.1182/blood-2004-12-4794

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15).

Authors:  Roberto Rosati; Roberta La Starza; Angelo Veronese; Ana Aventin; Christine Schwienbacher; Teresa Vallespi; Massimo Negrini; Massimo F Martelli; Cristina Mecucci
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

2.  Novel NUP98-HOXC11 fusion gene resulted from a chromosomal break within exon 1 of HOXC11 in acute myeloid leukemia with t(11;12)(p15;q13).

Authors:  Takeshi Taketani; Tomohiko Taki; Noriko Shibuya; Akira Kikuchi; Ryoji Hanada; Yasuhide Hayashi
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

3.  A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.

Authors:  Ajeeta B Dash; Ifor R Williams; Jeffery L Kutok; Michael H Tomasson; Ema Anastasiadou; Kathleen Lindahl; Shaoguang Li; Richard A Van Etten; Julian Borrow; David Housman; Brian Druker; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

4.  Stromal inhibition of megakaryocytic differentiation correlates with blockade of signaling by protein kinase C-epsilon and ERK/MAPK.

Authors:  A N Goldfarb; L L Delehanty; D Wang; F K Racke; I M Hussaini
Journal:  J Biol Chem       Date:  2001-06-06       Impact factor: 5.157

5.  The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11)(q31;p15).

Authors:  Takeshi Taketani; Tomohiko Taki; Noriko Shibuya; Etsuro Ito; Junichi Kitazawa; Kiminori Terui; Yasuhide Hayashi
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

6.  Regulation of c-Myc and Max in megakaryocytic and monocytic-macrophagic differentiation of K562 cells induced by protein kinase C modifiers: c-Myc is down-regulated but does not inhibit differentiation.

Authors:  A Lerga; P Crespo; M Berciano; M D Delgado; M Cañelles; C Calés; C Richard; E Ceballos; P Gutierrez; N Ajenjo; S Gutkind; J León
Journal:  Cell Growth Differ       Date:  1999-09

Review 7.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

8.  Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.

Authors:  Scott C Kogan; Jerrold M Ward; Miriam R Anver; Jules J Berman; Cory Brayton; Robert D Cardiff; John S Carter; Sherri de Coronado; James R Downing; Torgny N Fredrickson; Diana C Haines; Alan W Harris; Nancy Lee Harris; Hiroshi Hiai; Elaine S Jaffe; Ian C M MacLennan; Pier Paolo Pandolfi; Paul K Pattengale; Archibald S Perkins; R Mark Simpson; Mark S Tuttle; Joanne F Wong; Herbert C Morse
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

9.  Bethesda proposals for classification of lymphoid neoplasms in mice.

Authors:  Herbert C Morse; Miriam R Anver; Torgny N Fredrickson; Diana C Haines; Alan W Harris; Nancy L Harris; Elaine S Jaffe; Scott C Kogan; Ian C M MacLennan; Paul K Pattengale; Jerrold M Ward
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

Review 10.  Myelodysplastic syndrome overview.

Authors:  Razelle Kurzrock
Journal:  Semin Hematol       Date:  2002-07       Impact factor: 3.851

View more
  106 in total

1.  Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer.

Authors:  Marcos R H Estécio; Juan Gallegos; Céline Vallot; Ryan J Castoro; Woonbok Chung; Shinji Maegawa; Yasuhiro Oki; Yutaka Kondo; Jaroslav Jelinek; Lanlan Shen; Helge Hartung; Peter D Aplan; Bogdan A Czerniak; Shoudan Liang; Jean-Pierre J Issa
Journal:  Genome Res       Date:  2010-08-17       Impact factor: 9.043

2.  Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma.

Authors:  Sarah H Beachy; Masahiro Onozawa; Yang Jo Chung; Chris Slape; Sven Bilke; Princy Francis; Marbin Pineda; Robert L Walker; Paul Meltzer; Peter D Aplan
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

3.  Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner.

Authors:  Yahya S Al-Matary; Lacramioara Botezatu; Bertram Opalka; Judith M Hönes; Robert F Lams; Aniththa Thivakaran; Judith Schütte; Renata Köster; Klaus Lennartz; Thomas Schroeder; Rainer Haas; Ulrich Dührsen; Cyrus Khandanpour
Journal:  Haematologica       Date:  2016-07-07       Impact factor: 9.941

4.  Differential surface expression of CD18 and CD44 by neutrophils in bone marrow and spleen contributed to the neutrophilia in thalidomide-treated female B6C3F1 mice.

Authors:  Wimolnut Auttachoat; Jian Feng Zheng; Rui P Chi; Andrew Meng; Tai L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-22       Impact factor: 4.219

5.  Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.

Authors:  Claudia Hoemme; Abdul Peerzada; Gerhard Behre; Yipeng Wang; Michael McClelland; Kay Nieselt; Matthias Zschunke; Christine Disselhoff; Shuchi Agrawal; Fabienne Isken; Nicola Tidow; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

Review 6.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

7.  The fusion partner specifies the oncogenic potential of NUP98 fusion proteins.

Authors:  Jesslyn Saw; David J Curtis; Damian J Hussey; Alexander Dobrovic; Peter D Aplan; Christopher I Slape
Journal:  Leuk Res       Date:  2013-09-21       Impact factor: 3.156

8.  OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1.

Authors:  Ying-Wei Lin; Ramona Deveney; Mary Barbara; Norman N Iscove; Stephen D Nimer; Christopher Slape; Peter D Aplan
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

9.  Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl.

Authors:  Christopher Slape; Leah Y Liu; Sarah Beachy; Peter D Aplan
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

Review 10.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.